中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (12): 890-893.doi: 10.12144/zgmfskin202312890

• 临床研究 • 上一篇    下一篇

度普利尤单抗联合糖皮质激素治疗重症大疱性类天疱疮四例

邵丽芳,田蓉,孔维鑫,荆琪,袁小英   

  1. 空军特色医学中心皮肤科，北京，100142
  • 出版日期:2023-12-15 发布日期:2023-11-21

Dupilumab combined with glucocorticoid in the treatment of 4 cases with severe bullous pemphigoid

SHAO Lifang, TIAN Rong, KONG Weixin, JING Qi, YUAN Xiaoying   

  1. Department of Dermatology，Air Force Medical Center，PLA, Beijing 100142, China
  • Online:2023-12-15 Published:2023-11-21

PDF (PC)

96

摘要： 本文总结了4例应用度普利尤单抗联合糖皮质激素治疗重症大疱性类天疱疮的诊治经过，以期为重症大疱性类天疱疮的治疗提供借鉴。4例重症大疱性类天疱疮患者中，3例瘙痒明显伴嗜酸性粒细胞增多，糖皮质激素联合度普利尤单抗治疗后，分别于第2、3、1 d病情得到控制，第6、9、3 d嗜酸性粒细胞计数降至正常，第4、10、4 d后糖皮质激素开始减量。4例重症大疱性类天疱疮患者中1例合并肿瘤，无明显瘙痒感，嗜酸性粒细胞计数正常，用药10天后病情控制，14 d后糖皮质激素减量。度普利尤单抗联合糖皮质激素是治疗重症大疱性类天疱疮患者的有效方法。

关键词: 度普利尤单抗, 大疱性类天疱疮, 糖皮质激素

Abstract: We summarized 4 patients with severe bullous pemphigoid successfully treated by dupilumab combined with glucocorticoid, providing reference for the treatment of severe bullous pemphigoid. Of 4 patients, 3 had obvious itching accompanied by eosinophilia and the disease was controlled on day 2, 3, and 1st after treatment with glucocorticoid combined with dupriuzumab, respectively, the eosinophil count decreased to normal on day 6, 9, and 3rd, the dose of glucocorticoid began to be reduced on day 4, 10, and 4th. The other patient with concomitant tumors, had no obvious itching and normal eosinophil count, the condition was controlled after 10 days of medication, and the dose of glucocorticoid was reduced 14 days later.  Dupilumab combined with glucocorticoid is an effective method for the treatment of severe bullous pemphigoid patients.

Key words: dupilumab, bullous pemphigoid, glucocorticoid